Life Sciences

FDA warns Abbott for misleading promotion

Pharma Compliance Alert, February 4, 2009

Abbott Laboratories’ flashcard for Depakote and Depakote ER misbrands the drugs, according to an FDA warning letter posted January 29.

The flashcard omits risk information for Depakote and Depakote ER, broadens the indication of Depakote ER, omits indication information for Depakote, and omits material information about Depakote ER, according to the FDA.

Comments

0 comments on “FDA warns Abbott for misleading promotion

 

Most Popular